Hansa Biopharma AB Announces Positive Reimbursement Decision in Italy for Idefirix as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma announced that the Italian Medicine Agency has granted full access and reimbursement for the use of Idefirix, the company's first-in-class treatment, for the desensitization of highly... | December 8, 2022

Related Keywords

Italy ,Italian ,Hansa Biopharma ,Italian Medicine Agency ,Hansa Biopharma Ab Publ Stock Exchange ,News ,Information ,Press Release ,Mansa ,Iopharma ,Nnounced ,Hat ,The ,Medicine ,Agency ,Gas ,Granted ,Bull ,Access ,End ,Reimbursement ,Or ,Tse ,F ,Desensitization ,F Hnsa Se0002148817 ,